James Gorman - Agenus President
| AGEN Stock | USD 5.77 0.46 8.66% |
President
Dr. James R Gorman, M.D., Ph.D., is a Vice President Strategic Planning and Portfolio Management of the Company. Dr. Gorman joins Agenus with almost 20 years of experience in portfolio management, global pharmaceutical licensing and corporate development. He made his mark early on with Abbott Laboratories, where he was responsible for identifying, recommending and coordinating the strategy to grow Abbott biologics business. There he championed and executed the acquisition of Humira, a blockbuster antiTNF antibody with annual sales of over 14 billio nin 2015, which earned him the Abbott President Award. More recently he was the CoFounder, CEO and CMO of BioAssets Development Corporation, an antibody therapeutics business, which he shepherded from concept to a structured buyout by Cephalon Pharmaceuticals. Dr. Gorman was also the CoFounder, CEO and CSO of 121 Bio, LLC, a biopharmaceutical company with an IO focus since 2016.
| Tenure | 8 years |
| Address | 3 Forbes Road, Lexington, MA, United States, 02421-7305 |
| Phone | 781 674 4400 |
| Web | https://www.agenusbio.com |
Agenus Management Efficiency
The company has return on total asset (ROA) of (0.2751) % which means that it has lost $0.2751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7883) %, meaning that it created substantial loss on money invested by shareholders. Agenus' management efficiency ratios could be used to measure how well Agenus manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Equity is likely to grow to 1.61, while Return On Tangible Assets are likely to drop (0.91). At this time, Agenus' Debt To Assets are very stable compared to the past year. As of the 23rd of April 2024, Asset Turnover is likely to grow to 0.52, while Non Currrent Assets Other are likely to drop about 3.5 M.Management Performance
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.28 |
Agenus Inc Leadership Team
Elected by the shareholders, the Agenus' board of directors comprises two types of representatives: Agenus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agenus. The board's role is to monitor Agenus' management team and ensure that shareholders' interests are well served. Agenus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agenus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Stein, Chief Scientific Officer | ||
| James Gorman, Vice President - Strategic Planning and Portfolio Management | ||
| Ozer Baysal, Chief Bus. Officer | ||
| Regina Grebla, VP Communications | ||
| Shalini Sharp, Director | ||
| John Castle, Head Bioinformatics | ||
| Zack Armen, Head Relations | ||
| Wadih Jordan, Independent Director | ||
| Christine Klaskin, Principal Accounting Officer and VP of Fin. | ||
| Jennifer Buell, Pres Therapeutics | ||
| Don Vidic, Vice President Head of Commercial | ||
| Brian Corvese, Independent Director | ||
| Todd MD, Member Advisor | ||
| Karen Valentine, Chief Compliance Officer, VP, General Counsel and Secretary | ||
| Evan Ballantyne, CFO | ||
| Timothy Wright, Lead Independent Director | ||
| Christian Cortis, Chief Strategy Officer and Head of Finance | ||
| Julie DeSander, Chief Officer | ||
| Alfred Dadson, Chief Officer | ||
| Eric Humes, Chief Officer | ||
| Ulf Wiinberg, Director | ||
| Alexander Duncan, CTO and Head - Research | ||
| Dhan Chand, Scientific Discovery | ||
| Tracy Clemente, Chief Officer | ||
| Allison JeynesEllis, Director | ||
| Garo Armen, Founder, Executive Chairman, CEO and Chairman of Bus. and Devel. Advisory Committee | ||
| JeanMarie Cuillerot, Chief Medical Officer | ||
| Craig Winter, Chief Officer | ||
| Robin JD, Chief Officer | ||
| Stephanie Fagan, Chief Officer | ||
| Shahzad Malik, Independent Director | ||
| Evan Kearns, Vice President General Counsel, Secretary |
Agenus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agenus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (1.57) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 149.89 M | ||||
| Shares Outstanding | 20.95 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 59.26 % | ||||
| Number Of Shares Shorted | 47.72 M | ||||
| Price To Earning | 10.52 X |
Pair Trading with Agenus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agenus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agenus will appreciate offsetting losses from the drop in the long position's value.Moving together with Agenus Stock
| 0.63 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.77 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Agenus Stock
| 0.75 | ELYM | Eliem Therapeutics | PairCorr |
| 0.47 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Agenus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agenus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agenus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agenus Inc to buy it.
The correlation of Agenus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agenus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agenus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agenus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Agenus Inc information on this page should be used as a complementary analysis to other Agenus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Agenus Stock analysis
When running Agenus' price analysis, check to measure Agenus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agenus is operating at the current time. Most of Agenus' value examination focuses on studying past and present price action to predict the probability of Agenus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agenus' price. Additionally, you may evaluate how the addition of Agenus to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Agenus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.80) | Revenue Per Share 8.735 | Quarterly Revenue Growth 1.952 | Return On Assets (0.28) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.